This recombinant monoclonal antibody is designed as a research-grade biosimilar to Aletekitug, targeting interleukin-18 (IL-18), a proinflammatory cytokine belonging to the IL-1 superfamily. IL-18 plays a critical role in immune regulation by promoting interferon-gamma production and enhancing both innate and adaptive immune responses. This cytokine is involved in the polarization of T helper cells and activation of natural killer cells. Dysregulated IL-18 signaling has been implicated in various inflammatory and autoimmune conditions, including adult-onset Still's disease, systemic juvenile idiopathic arthritis, macrophage activation syndrome, and hemophagocytic lymphohistiocytosis, as well as metabolic disorders and cardiovascular diseases.
Aletekitug is a therapeutic antibody developed to neutralize IL-18 activity and has been investigated in clinical trials for treating inflammatory conditions characterized by excessive IL-18 production. This biosimilar provides researchers with a valuable tool for investigating IL-18-mediated pathways, studying cytokine networks in inflammatory diseases, and exploring potential therapeutic interventions targeting this cytokine. It supports investigations into immune dysregulation and the pathophysiology of IL-18-driven disorders.
Email: support@cusabio.com
Distributors Worldwide